Latest Insider Transactions at Phreesia, Inc. (PHR)
This section provides a real-time view of insider transactions for Phreesia, Inc. (PHR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Phreesia, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Phreesia, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 14
2023
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,000
-1.66%
|
$40,000
$20.16 P/Share
|
|
Sep 14
2023
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
2,210
-1.86%
|
$44,200
$20.17 P/Share
|
|
Sep 14
2023
|
Michael J. Davidoff SVP, Payer Business |
SELL
Open market or private sale
|
Direct |
2,953
-3.06%
|
$59,060
$20.16 P/Share
|
|
Sep 13
2023
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,907
-0.26%
|
$78,140
$20.75 P/Share
|
|
Sep 13
2023
|
Janet Gunzburg Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
934
-1.11%
|
$18,680
$20.75 P/Share
|
|
Sep 13
2023
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,826
-0.74%
|
$36,520
$20.75 P/Share
|
|
Sep 13
2023
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
3,256
-1.34%
|
$65,120
$20.75 P/Share
|
|
Sep 13
2023
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
119
-0.74%
|
$2,380
$20.75 P/Share
|
|
Sep 13
2023
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
2,059
-0.47%
|
$41,180
$20.75 P/Share
|
|
Sep 13
2023
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,555
-0.26%
|
$131,100
$20.75 P/Share
|
|
Sep 13
2023
|
Michael J. Davidoff SVP, Payer Business |
SELL
Open market or private sale
|
Direct |
3,606
-1.8%
|
$72,120
$20.75 P/Share
|
|
Sep 13
2023
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,957
-2.19%
|
$79,140
$20.75 P/Share
|
|
Sep 12
2023
|
Evan Roberts Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,559
+0.87%
|
-
|
|
Sep 12
2023
|
Janet Gunzburg Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,404
+5.41%
|
-
|
|
Sep 12
2023
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
3,826
+3.03%
|
-
|
|
Sep 12
2023
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
5,466
+4.3%
|
-
|
|
Sep 12
2023
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Indirect |
273
+3.27%
|
-
|
|
Sep 12
2023
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
11,853
+1.78%
|
$59,265
$5.82 P/Share
|
|
Sep 12
2023
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
3,279
+1.56%
|
-
|
|
Sep 12
2023
|
Chaim Indig Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,260
+0.89%
|
-
|
|
Sep 12
2023
|
Michael J. Davidoff SVP, Payer Business |
BUY
Grant, award, or other acquisition
|
Direct |
6,559
+6.15%
|
-
|
|
Sep 12
2023
|
Balaji Gandhi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,406
+6.61%
|
-
|
|
Sep 08
2023
|
Evan Roberts Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+3.87%
|
$60,000
$2.03 P/Share
|
|
Aug 24
2023
|
Allison C Hoffman General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
11,042
-8.67%
|
$287,092
$26.39 P/Share
|
|
Jul 31
2023
|
Janet Gunzburg Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
272
-0.68%
|
$8,432
$31.72 P/Share
|
|
Jul 31
2023
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
315
+0.7%
|
$9,765
$31.72 P/Share
|
|
Jul 31
2023
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
315
+1.04%
|
$9,765
$31.72 P/Share
|
|
Jul 31
2023
|
Gillian Munson Director |
BUY
Grant, award, or other acquisition
|
Direct |
315
+1.21%
|
$9,765
$31.72 P/Share
|
|
Jul 21
2023
|
Michael J. Davidoff SVP, Payer Business |
SELL
Open market or private sale
|
Direct |
1,075
-1.14%
|
$33,325
$31.75 P/Share
|
|
Jul 14
2023
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
624
-0.52%
|
$20,592
$33.72 P/Share
|
|
Jul 14
2023
|
Michael J. Davidoff SVP, Payer Business |
SELL
Payment of exercise price or tax liability
|
Direct |
1,122
-1.17%
|
$37,026
$33.72 P/Share
|
|
Jul 14
2023
|
Balaji Gandhi Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
807
-0.95%
|
$26,631
$33.72 P/Share
|
|
Jul 14
2023
|
Allison C Hoffman General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
1,172
-0.91%
|
$38,676
$33.72 P/Share
|
|
Jul 14
2023
|
Chaim Indig Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,089
-0.25%
|
$101,937
$33.72 P/Share
|
|
Jul 14
2023
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
1,948
-0.95%
|
$64,284
$33.72 P/Share
|
|
Jul 14
2023
|
Evan Roberts Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,781
-0.25%
|
$58,773
$33.72 P/Share
|
|
Jul 13
2023
|
Lisa Egbuonu Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,049
+41.43%
|
-
|
|
Jul 08
2023
|
Balaji Gandhi Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
861
-1.0%
|
$24,108
$28.87 P/Share
|
|
Jun 30
2023
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
201
+0.16%
|
$5,226
$26.21 P/Share
|
|
Jun 30
2023
|
Janet Gunzburg Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
148
+0.37%
|
$3,848
$26.21 P/Share
|
|
Jun 28
2023
|
Gillian Munson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,051
+19.26%
|
-
|
|
Jun 28
2023
|
Ramin Sayar Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,051
+24.91%
|
-
|
|
Jun 28
2023
|
Mark Douglas Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,051
+21.45%
|
-
|
|
Jun 28
2023
|
Michael Weintraub Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,051
+3.24%
|
-
|
|
Jun 28
2023
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,051
+12.05%
|
-
|
|
Jun 28
2023
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,051
+16.9%
|
-
|
|
Jun 17
2023
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Indirect |
27
-0.34%
|
$837
$31.79 P/Share
|
|
Jun 17
2023
|
Janet Gunzburg Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
117
-0.29%
|
$3,627
$31.79 P/Share
|
|
Jun 16
2023
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Indirect |
67
-0.85%
|
$2,077
$31.79 P/Share
|
|
Jun 15
2023
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Indirect |
40
-0.5%
|
$1,320
$33.44 P/Share
|